Amivantamab, a bsAb targeting EGFR and MET (91), was developed by Janssen Biotechnology and approved by the FDA in May 2021 for patients with non-small cell lung cancer (NSCLC) whose tumors have EGFR exon 20 insertion mutations (92). The gene discussed is MET; the disease is non-small cell lung carcinoma.